Nurix Therapeutics recently reported Phase 1 data showing its BTK degrader bexobrutideg (NX-5948) achieved a 75% objective response rate in patients with relapsed or refractory Waldenström ...
As embodied intelligence emerges as the next frontier, a new company has joined the race. ACE Robotics, led by Wang Xiaogang, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback